ArticleCNS neuroscience & therapeutics2026
Nonlinear Association Between the C-Reactive Protein-To-Albumin Ratio and Post-Stroke Epilepsy Risk.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe C-reactive protein-to-albumin ratio (CAR) is an integrated biomarker of inflammation and nutritional status. Its potential association with the risk of post-stroke epilepsy (PSE) after ischemic stroke (IS) requires comprehensive evaluation.
methodsWe analyzed data from 21,459 IS patients admitted to hospitals in Chongqing, China, between June 2017 and July 2023. CAR was calculated from admission laboratory values. The primary outcome was the development of PSE within 1 year. Multivariable logistic regression with three progressively adjusted models was used to control for demographic factors, stroke severity (NIHSS), comorbidities, neuroimaging findings, and extensive laboratory parameters. A restricted cubic spline (RCS) analysis explored the relationship's nonlinearity. Subgroup and sensitivity analyses tested robustness.
resultsElevated admission CAR was independently associated with increased PSE risk. After full adjustment, each unit increase in CAR yielded an odds ratio (OR) of 1.88 (95% CI: 1.64-2.16, p < 0.001). The ROC analysis showed that the AUC for CAR in predicting PSE was 0.84 (95% CI: 0.83-0.85). RCS analysis revealed a significant nonlinear relationship (p-nonlinearity < 0.001) with an inflection point at CAR = 1.15. A pronounced dose-response relationship was observed across CAR quartiles, with the highest quartile (Q4) showing a substantially elevated risk (adjusted OR = 34.42, 95% CI: 18.58-69.70) compared to the lowest (Q1). Subgroup analyses indicated particularly strong associations in patients with diabetes, coronary artery disease, and middle cerebral artery involvement, confirmed by sensitivity analyses.
conclusionCAR is a potent, independent predictor of PSE in IS patients, demonstrating a nonlinear, threshold-based relationship. As an integrative marker, it may enhance early risk stratification and guide personalized interventions, warranting further prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.